Rapport Therapeutics RAPP
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 73rd percentile, 5-year average -11.0x
Near the top of its 5-year range · 83rd percentile, 5-year average 1.1x
#4114 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 83rd percentile, 5-year average 19.9x
#4918 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.96 | – | 1.10 | 83% (pricier than usual) | #4114 of 5331 (1 = cheapest) |
| PE | -8.25 | -6.75 | -10.97 | 73% (pricier than usual) | – |
| PS | 77.51 | 218,332.72 | 19.86 | 83% (pricier than usual) | #4918 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on RAPP.
Sign in to join the discussion.